1sho
From Proteopedia
| Line 1: | Line 1: | ||
[[Image:1sho.jpg|left|200px]] | [[Image:1sho.jpg|left|200px]] | ||
| - | + | <!-- | |
| - | + | The line below this paragraph, containing "STRUCTURE_1sho", creates the "Structure Box" on the page. | |
| - | + | You may change the PDB parameter (which sets the PDB file loaded into the applet) | |
| - | + | or the SCENE parameter (which sets the initial scene displayed when the page is loaded), | |
| - | + | or leave the SCENE parameter empty for the default display. | |
| - | + | --> | |
| - | | | + | {{STRUCTURE_1sho| PDB=1sho | SCENE= }} |
| - | | | + | |
| - | + | ||
| - | }} | + | |
'''CRYSTAL STRUCTURE OF VANCOMYCIN AT ATOMIC RESOLUTION''' | '''CRYSTAL STRUCTURE OF VANCOMYCIN AT ATOMIC RESOLUTION''' | ||
| Line 19: | Line 16: | ||
==About this Structure== | ==About this Structure== | ||
| - | + | Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1SHO OCA]. | |
==Reference== | ==Reference== | ||
Crystal structure of vancomycin., Schafer M, Schneider TR, Sheldrick GM, Structure. 1996 Dec 15;4(12):1509-15. PMID:[http://www.ncbi.nlm.nih.gov/pubmed/8994975 8994975] | Crystal structure of vancomycin., Schafer M, Schneider TR, Sheldrick GM, Structure. 1996 Dec 15;4(12):1509-15. PMID:[http://www.ncbi.nlm.nih.gov/pubmed/8994975 8994975] | ||
| - | [[Category: Protein complex]] | ||
[[Category: Sheldrick, G M.]] | [[Category: Sheldrick, G M.]] | ||
| - | [[Category: | + | [[Category: Glycopeptide antibiotic]] |
| - | + | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sat May 3 08:42:58 2008'' | |
| - | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on | + | |
Revision as of 05:42, 3 May 2008
CRYSTAL STRUCTURE OF VANCOMYCIN AT ATOMIC RESOLUTION
Overview
BACKGROUND: Vancomycin and other related glycopeptide antibiotics are clinically very important because they often represent the last line of defence against bacteria that have developed resistance to antibiotics. Vancomycin is believed to act by binding nascent cell wall mucopeptides terminating in the sequence D-Ala-D-Ala, weakening the resulting cell wall. Extensive NMR and other studies have shown that the formation of asymmetric antibiotic dimers is important in peptide binding. Despite intensive efforts the crystal structure of vancomycin has been extremely difficult to obtain, partly because high-resolution data were unavailable, and partly because the structure was too large to be solved by conventional "direct methods'. RESULTS: Using low-temperature synchrotron X-ray data combined with new ab initio techniques for solving the crystallographic phase problem, we have succeeded in determining the crystal structure of vancomycin at atomic resolution. The structure provides much detailed information that should prove invaluable in modelling and mechanistic studies. CONCLUSIONS: Our structure confirms that vancomycin exists as an asymmetric dimer. The dimer conformation allows the docking of two D-Ala-D-Ala peptides in opposite directions; these presumably would be attached to different glycopeptide strands. In the crystal, one of the binding pockets is occupied by an acetate ion that mimics the C terminus of the nascent cell wall peptide; the other is closed by the asparagine sidechain, which occupies the place of a ligand. The occupied binding pocket exhibits high flexibility but the closed binding pocket is relatively rigid. We propose that the asparagine sidechain may hold the binding pocket in a suitable conformation for peptide docking, swinging out of the way when the peptide enters the binding pocket.
About this Structure
Full crystallographic information is available from OCA.
Reference
Crystal structure of vancomycin., Schafer M, Schneider TR, Sheldrick GM, Structure. 1996 Dec 15;4(12):1509-15. PMID:8994975 Page seeded by OCA on Sat May 3 08:42:58 2008
